Panelists discuss how integrating both intravenous (IV) and subcutaneous (SubQ) therapies in oncology centers requires adaptable staffing, data-driven workflow planning, and thoughtful pilot ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

FDA approved pembrolizumab and berahyaluronidase alfa-pmph for patients aged 12 and older with solid tumors. Study MK-3475A-D77 showed a 45% ORR in subcutaneous administration for treatment-naïve ...

The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...